FDA approves generic pediatric antibiotic

Article

The Food and Drug Administration gave the okay to Ranbaxy Laboratories for its pediatric formulation of the generic antibiotic cefuroxime axetil.

The Food and Drug Administration gave the okay to Ranbaxy Laboratories for its pediatric formulation of the generic antibiotic cefuroxime axetil.

The drug, which is also sold as GlaxoSmithKline's Ceftin, is indicated for treatment of mild to moderate pharyngitis/tonsillitis, acute bacterial otitis media, and impetigo in patients 3 months to 12 years old. Two dose sizes have been approved, 125 mg/5 ml and 250 mg/5 ml.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
David Brousseau, MD, highlights impact of timely opioid dosing in pediatric sickle cell pain
Richard Bermudes, MD, on screen-related addictions and youth mental health
© 2025 MJH Life Sciences

All rights reserved.